<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Deficiencies of <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> occur as <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic disorders</z:e> or may be presenting features of underlying disease </plain></SENT>
<SENT sid="1" pm="."><plain>Familial <z:chebi fb="6" ids="39025">high density lipoprotein</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi>), or alpha-<z:chebi fb="1" ids="6495">lipoprotein</z:chebi>, deficiency so far described includes <z:e sem="disease" ids="C0039292" disease_type="Disease or Syndrome" abbrv="HDLDT1">Tangier disease</z:e>, Lecithin: cholesterol acyltransferase (LCAT) deficiency, A-I Variants syndrome and <z:e sem="disease" ids="C0342895" disease_type="Disease or Syndrome" abbrv="FED">Fish-eye disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In 1981 Vergani described a familial aggregation of <z:hpo ids='HP_0003233'>low HDL-cholesterol</z:hpo> (less than 33 mg/dl) and Apo A (about 50% of <z:mpath ids='MPATH_458'>normal</z:mpath> levels) in the presence of <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="1" ids="39027">VLDL</z:chebi> and <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>LCAT and <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> lipase activities, both extrahepatic and hepatic, were <z:mpath ids='MPATH_458'>normal</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>By zonal ultracentrifugation HDL2 subclass was found to be reduced </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="17" ids="39025">HDL</z:chebi> <z:chebi fb="0" ids="13850">apoproteins</z:chebi>, examined by isoelectric focusing in <z:chebi fb="0" ids="53656">polyacrylamide</z:chebi> gel, were qualitatively <z:mpath ids='MPATH_458'>normal</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>No disorders to which low levels of <z:chebi fb="17" ids="39025">HDL</z:chebi> might be secondary (e.g., overweight, cigarette smoking, <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disease</z:e>) are present in the affected members </plain></SENT>
<SENT sid="7" pm="."><plain>The underlying biochemical defect is unknown but probably involves altered synthesis or catabolism of <z:chebi fb="17" ids="39025">HDL</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Familial <z:e sem="disease" ids="C0473527" disease_type="Disease or Syndrome" abbrv="">hypo-alpha-lipoproteinemia</z:e> is accompanied by a high prevalence of premature <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> and <z:hpo ids='HP_0001699'>sudden death</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>The genetic analysis of the disorder is consistent with autosomal <z:hpo ids='HP_0000005'>inheritance</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>The criteria for the definition of familial <z:e sem="disease" ids="C0473527" disease_type="Disease or Syndrome" abbrv="">hypo-alpha-lipoproteinemia</z:e> are, therefore, as follows: 1) <z:hpo ids='HP_0003233'>low HDL-cholesterol</z:hpo> level in the presence of <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="1" ids="39027">VLDL</z:chebi> and <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> levels; 2) absence of diseases or factors to which <z:e sem="disease" ids="C0473527" disease_type="Disease or Syndrome" abbrv="">hypo-alpha-lipoproteinemia</z:e> might be secondary; 3) presence of a similar <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> pattern in a first degree relative </plain></SENT>
</text></document>